News & Updates

Ixekizumab effective for difficult-to-treat psoriatic arthritis
Ixekizumab effective for difficult-to-treat psoriatic arthritis
08 Dec 2021 byAudrey Abella

The monoclonal antibody ixekizumab improved the signs and symptoms of psoriatic arthritis (PsA) in PsA patients with inadequate response to one or two tumour necrosis factor inhibitors (TNFis), suggests results from a post hoc subanalysis of the SPIRIT-P2 trial.

Ixekizumab effective for difficult-to-treat psoriatic arthritis
08 Dec 2021
Tonsillectomy may lower risk of psoriasis
Tonsillectomy may lower risk of psoriasis
27 Nov 2021

Patients who received tonsillectomy have a lower risk of psoriasis, reports a study, following adjustment for baseline characteristics, comorbidities, and medical confounders relative to a comparison group.

Tonsillectomy may lower risk of psoriasis
27 Nov 2021
Hidradenitis suppurativa bidirectionally linked to atopic dermatitis
Hidradenitis suppurativa bidirectionally linked to atopic dermatitis
27 Nov 2021
Patients with vitiligo at risk of hearing loss
Patients with vitiligo at risk of hearing loss
27 Nov 2021

A significant association exists between vitiligo and sensorineural hearing loss (SNHL), according to a recent study, which recommends audiologic assessment for early recognition and management of hearing loss in patients with vitiligo.

Patients with vitiligo at risk of hearing loss
27 Nov 2021